Gilead profited by delaying new version of a drug, NY Times reports

Gilead Sciences decided to stop pursuing a new H.I.V. drug in 2004 and told the public it wasn’t different enough from current treatments, Rebecca Robbins and Sheryl Gay Stolberg of The New York Times reports. However, Gilead had actually devised a plan to delay the new drug’s release to extend their patents, despite executives believing the new drug might turn out to be a safer option for patients, the Times said, citing internal documents made public in a litigation against the company.